Search Results

You are looking at 51 - 60 of 383 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Hans F. Schoellhammer, Gagandeep Singh, and Lucille Leong

Practice Guidelines in Oncology for Rectal Cancer recommendations for the management of potentially resectable synchronous metastatic disease Describe the role of chemotherapy with bevacizumab in the conversion of CRLM to resectable status Case

Full access

or metastatic disease that progresses following initial therapy with 5-FU/leucovorin plus bevacizumab. The following parameters were added for reporting of pathologic stage: lymphovascular invasion, perineural invasion, and extra nodal tumor

Full access

Andrew H. Ko and Margaret A. Tempero

: 131 – 138 . 55 Kindler HL Friberg G Stadler WM . Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr) . In: Proceedings of the American Society

Full access

F. Anthony Greco

cancer of unknown primary: from autopsy to microarray . Eur J Cancer 2007 ; 43 : 2026 – 2036 . 3. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J

Full access

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

provided in Table 2 . The most common combination was a fluoropyrimidine plus oxaliplatin with or without bevacizumab (37% and 33%, respectively). The remaining patients either received fluoropyrimidine/irinotecan or single-agent fluoropyrimidine

Full access

Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang

hypermetabolic nodules in left hilar suggestive of lung cancer with obstructive pneumonia and bone and right adrenal metastases. (B1–B3) CT after 2 cycles of carboplatin/pemetrexed with bevacizumab shows left lower lobe atelectasis aggravated with a large

Full access

Philip J. Saylor and M. Dror Michaelson

trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med 2003 ; 349 : 427 – 434 . 7 Yang JC Sherry RM Steinberg SM . Randomized study of high-dose and low-dose interleukin-2 in

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

categories based on the reason for discordance, including (1) therapy mismatched with hormone receptor (HR) or HER2 status, (2) HER2-targeted therapy without chemotherapy, (3) nonapproved bevacizumab use, (4) adjuvant regimens received in the metastatic

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook

with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use

Full access

Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad

Background: PTL is a prognostic factor for mCRC. Recent data suggest PTL is also predictive of survival benefit with cetuximab (CET) and bevacizumab (BEV). This study evaluated the prognostic and predictive effect of PTL in patients with KRAS WT